Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abd Elkader B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G. Barda N, et al. Among authors: kliker l. Clin Microbiol Infect. 2023 Jul;29(7):918-923. doi: 10.1016/j.cmi.2023.03.007. Epub 2023 Mar 13. Clin Microbiol Infect. 2023. PMID: 36921715 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 34023883
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.
Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, Sapir E, Mor O, Alroy-Preis S, Mendelson E, Mandelboim M. Lustig Y, et al. Among authors: kliker l. Euro Surveill. 2021 Jul;26(26):2100557. doi: 10.2807/1560-7917.ES.2021.26.26.2100557. Euro Surveill. 2021. PMID: 34212838 Free PMC article.
Sensitive Immunodetection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern 501Y.V2 and 501Y.V1.
Barlev-Gross M, Weiss S, Paran N, Yahalom-Ronen Y, Israeli O, Nemet I, Kliker L, Zuckerman N, Glinert I, Noy-Porat T, Alcalay R, Rosenfeld R, Levy H, Mazor O, Mandelboim M, Mendelson E, Beth-Din A, Israely T, Mechaly A. Barlev-Gross M, et al. Among authors: kliker l. J Infect Dis. 2021 Aug 16;224(4):616-619. doi: 10.1093/infdis/jiab278. J Infect Dis. 2021. PMID: 34398244 Free PMC article.
The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R.
Mor O, Mandelboim M, Fleishon S, Bucris E, Bar-Ilan D, Linial M, Nemet I, Kliker L, Lustig Y, Israel National Consortium For Sars-CoV-Sequencing, Mendelson ES, Zuckerman NS. Mor O, et al. Among authors: kliker l. Vaccines (Basel). 2021 Aug 23;9(8):937. doi: 10.3390/vaccines9080937. Vaccines (Basel). 2021. PMID: 34452062 Free PMC article.
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y, Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H, Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L, Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. Makdasi E, et al. Among authors: kliker l. Cell Rep. 2021 Sep 7;36(10):109679. doi: 10.1016/j.celrep.2021.109679. Epub 2021 Aug 21. Cell Rep. 2021. PMID: 34464610 Free PMC article.
The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021.
Zuckerman N, Nemet I, Kliker L, Atari N, Lustig Y, Bucris E, Bar Ilan D, Geva M, Sorek-Abramovich R, Weiner C, Rainy N, Bar-Chaim A, Benveniste-Levkovitz P, Abu Hamed R, Regev-Yochay G, Hevkin O, Mor O, Alroy-Preis S, Mendelson E, Mandelboim M. Zuckerman N, et al. Among authors: kliker l. Euro Surveill. 2021 Nov;26(45):2100974. doi: 10.2807/1560-7917.ES.2021.26.45.2100974. Euro Surveill. 2021. PMID: 34763751 Free PMC article.
Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
Gilboa M, Mandelboim M, Indenbaum V, Lustig Y, Cohen C, Rahav G, Asraf K, Amit S, Jaber H, Nemet I, Kliker L, Bar-Haim E, Mendelson E, Doolman R, Rubin C, Regev-Yochay G, Kreiss Y. Gilboa M, et al. Among authors: kliker l. J Infect Dis. 2022 Mar 2;225(5):785-792. doi: 10.1093/infdis/jiab584. J Infect Dis. 2022. PMID: 34850049
36 results